Silver Creek’s mission is to develop Smart Growth Factors™ into life-changing therapies for patients suffering from acute organ or tissue damage. Our lead asset, scp776, is currently in Phase II development for acute ischemic stroke.
Scp776 is a Smart Growth Factor™ designed to optimize delivery of insulin growth factor I (IGF1). IGF1 is known to enhance apoptotic escape in injured tissues through well-characterized, pleiotropic mechanisms.
Natural IGF1 is rapidly captured by IGF binding proteins, precluding effective delivery to injured cells. Scp776 has been engineered to enable a long half-life, while simultaneously targeting apoptotic cells, thereby mitigating off-target effects.
Scp776 has been shown to reduce scar size and improve function in pre-clinical models of acute organ injuries. Non-human primate models have demonstrated an unprecedented survival benefit in stroke.
This independent review provides a comprehensive overview of the clinical and preclinical evidence supporting IGF1 as a therapeutic target in acute ischemic stroke.
Stroke is one of the world’s leading causes of death and disability. Nearly 700,000 patients in the US alone suffer from ischemic strokes each year. Acute treatment options are limited to clot removal, with medicines or with surgery.
Even with clot removal, only 30-45% of patients achieve good clinical outcomes at 90 days. This is likely due to the injury sustained by the brain tissue before the blocked vessel is opened.
ARPEGGIO (NCT05585606) is a randomized, placebo-controlled Phase II study evaluating the safety and neuroprotective capacity of scp776 in subjects undergoing endovascular thrombectomy for acute ischemic stroke.
